An Examination of the Antioxidant Capacity, Antibacterial Activity and Toxicity of Commercial Kale and Spirulina Powders

Clémence Blanc^{1,2}, Ian Edwin Cock^{1,3,*}¹Environmental Futures Research Institute, Griffith University, Brisbane, AUSTRALIA.²School of Biology, Ecole de Biologie Industrielle (EBI), Cergy, FRANCE.³School of Environment and Science, Griffith University, Brisbane, AUSTRALIA.

ABSTRACT

Introduction: The development of antibiotic resistant bacteria has resulted in treatment failure for the current antibiotic regimen against many bacteria. A corresponding decrease in the development of new antibiotic therapies has highlighted the urgent need for the discovery of new antibiotics. An examination of 'superfoods' is an attractive option due to the high antioxidant capacities and beneficial secondary compounds reported in many 'superfoods'. This study was undertaken to test kale and spirulina extracts for the ability to inhibit the growth of a panel of bacterial pathogens of human importance. **Methods:** Commercially sourced kale and spirulina powders were extracted and tested for antimicrobial activity using modified disc diffusion and liquid dilution MIC methods. Toxicity was evaluated using an *Artemia franciscana* nauplii bioassay. **Results:** The methanolic and aqueous extracts of kale and spirulina displayed noteworthy growth inhibitory activity against *P. mirabilis*. The aqueous spirulina extract was a particularly good inhibitor of *P. mirabilis*, with MIC values as low as 220 µg/mL. In contrast, all extracts were ineffective or of low inhibitory activity against all other bacteria tested. All extracts were

non-toxic in the *Artemia* nauplii bioassay, confirming their suitability as natural antibacterial therapies. **Conclusion:** These studies indicate that aqueous kale and spirulina extracts are promising inhibitors of *P. mirabilis* growth and may be useful in the prevention and treatment of rheumatoid arthritis, as well as other diseases caused by that bacterium.

Key words: Antibacterial activity, Natural therapies, Superfood, *Brassica oleracea*, *Arthrospira*, *Artemia*, Toxicity.

Correspondence:

Dr. Ian Edwin Cock

¹School of Environment and Science, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland, AUSTRALIA.³Environmental Futures Research Institute, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland, AUSTRALIA.

Phone no: +61 7 37357637

E-mail: i.cock@griffith.edu.au

DOI: 10.5530/pc.2021.1.10

INTRODUCTION

Plants have been used for thousands of years as medicines for treating a variety of different diseases (including fighting bacterial pathogens) by most, if not all civilisations globally. Indeed, the ability of plant extracts to block the growth of pathogenic bacteria has become a focus of substantial recent study.¹⁻⁵ Much of the research into traditional medicinal plant use has focused on Asian,⁶⁻⁸ African,⁹⁻¹¹ Middle Eastern¹²⁻¹⁴ and South American¹⁵ plants. However, despite the potential of plants to provide us with useful pharmaceutical agents, the field is still relatively poorly studied. Only an estimated 5-10% of the approximately 300,000-500,000 plant species worldwide have been screened for one or more bioactivities.⁹

The development of new antibiotic therapies is particularly urgent. The recent establishment of bacterial pathogens that are either extremely (XDR) or totally resistant (TDR) to common clinically used antibiotics¹⁶ has resulted in the need to develop new and effective antibiotic chemotherapies. There are now limited therapeutic options for many diseases caused by bacterial pathogens and the situation is expected to worsen in the future as bacteria exchange resistance genes. Indeed, the development of alternative antibacterial treatment modalities has become crucial and is considered by the World Health Organisation (WHO) to be one of the most serious challenges facing medical science.¹⁷ For reasons reviewed elsewhere,¹⁶ it is unlikely that the previous methods of antibiotic discovery/development will be as successful in the future and new treatment modalities are urgently required. Traditional medicines and herbal remedies have great potential for antimicrobial drug development and there has recently been a substantial increase in interest in this field.¹⁸⁻³²

The consumption of 'superfoods' may be beneficial to human health, both in healthy individuals and in people suffering from disease. These

foods have high levels of one or more important dietary components and may provide necessary nutrients and macromolecules to assist in maintaining a healthy nutritional balance, thereby decreasing the occurrence of disease. This may be achieved in a number of ways, including boosting the individual's immune system, increasing metabolism and enhancing cellular protection mechanisms. Foods with high antioxidant contents may be particularly beneficial as high antioxidant levels assist in preventing the development of degenerative diseases such as cancer.³³ Cardiovascular diseases,³⁴ neural degeneration,³⁵ diabetes and obesity.³⁶ Phenolic phytochemicals are generally strong antioxidants.³⁷ Their primary action involves the protection of cell constituents against oxidative damage through the scavenging of free radicals, thereby averting their deleterious effects on nucleic acids, proteins, and lipids in cells.³⁷ Furthermore, 'superfoods' may contain high levels of secondary metabolites which may directly target bacterial pathogens, thereby preventing and treating pathogen infections. Therefore, superfoods may be good targets for screening for new antibacterial chemotherapies.

Brassica oleracea L. (commonly known as kale) is described as a 'superfood' due to its high levels of antioxidant vitamins. It is particularly rich in Vitamins A, C, B₁, B₂, B₆, E, folate and pantothenic acid.³⁸ It is also a rich source of several important dietary minerals, including iron, calcium, potassium, phosphates and manganese. Spirulina is an edible biomass of three species of cyanobacterium: *Arthrospira platensis*, *Arthrospira fusiformis* and *Arthrospira maxima*. It is a particularly rich source of protein (up to 70% of the dry weight), and also contains high levels of Vitamins B₁, B₂, B₆, manganese and iron.³⁸ It is also rich in the fatty acids, gamma-linolenic acid, alpha-linolenic acid, linoleic acid, stearidonic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid, yet contains no detectable levels

of Omega-3 fatty acids. The high contents of antioxidant vitamins and minerals of these two 'superfoods' makes them good targets for screening against bacterial pathogens that cause disease in humans. This study was undertaken to screen extracts produced from commercial kale and spirulina food additives against bacterial pathogens. The toxicity of the extracts was also determined to further evaluate their suitability for therapeutic use.

MATERIALS AND METHODS

Plant material and extraction

Commercially produced kale and spirulina food supplements were obtained from Nature's Way, Australia as pure dried powders. Individual 1g masses of the dried plant material was extracted extensively in 50 mL methanol, deionised water or ethyl acetate for 24h at 4°C with gentle shaking. All solvents were purchased from Ajax Fine Chemicals, Australia and were analytical (AR) grade. The extract was filtered through filter paper (Whatman No. 54) under vacuum followed by drying by rotary evaporation. The resultant pellet was dissolved in 5mL deionised water (containing 1% DMSO), passed through 0.22µm filter (Sarstedt) and stored at 4°C.

Qualitative phytochemical studies

Phytochemical analysis of the kale and spirulina extracts for the presence of saponins, phenolic compounds, flavonoids, phytosteroids, triterpenoids, cardiac glycosides, anthraquinones, tannins and alkaloids was conducted using standard assays.³⁹⁻⁴¹

Antioxidant capacity

The antioxidant capacity of each extract was assessed using the DPPH free radical scavenging method⁴² with modifications. Briefly, DPPH solution was prepared fresh each day as a 400 µM solution by dissolving DPPH (Sigma) in AR grade methanol (Ajax, Australia). A 2 mL aliquot of each extract was evaporated, and the residue resuspended in 2 mL of methanol. Each extract was added to a 96 well plate in 5, 10, 25, 50, 75µL volumes in triplicate. Methanol was added to each well to give a volume of 225µL. A volume of 75 µL of the fresh DPPH solution was added to each well to give a total reaction volume of 300 µL. Ascorbic acid was prepared fresh and examined across the range 0-25µg per well as a reference and the absorbances were recorded at 515nm. All tests and controls were performed in triplicate. The antioxidant capacity based on DPPH free radical scavenging ability was determined for each extract and expressed as µg ascorbic acid equivalents per gram of original plant material extracted.

Antibacterial screening

Test micro-organisms

All media was purchased from Oxoid Ltd., Australia. The reference strains of *A. baylyi* (ATCC21721), *Klebsiella pneumoniae* (ATCC31488), *Proteus mirabilis* (ATCC21721), *Proteus vulgaris* (ATCC21719) and *Pseudomonas aeruginosa* (ATCC39324) were purchased from American Tissue Culture Collection (ATCC), USA. Clinical isolate microbial strains of *Alcaligenes faecalis*, *Bacillus cereus*, *Enterobacter aerogenes*, *Enterococcus faecalis*, *Escherichia coli*, *Klebsiella pneumonia*, *Proteus mirabilis* and *Pseudomonas aeruginosa* were obtained from Ms Michelle Mendell and Ms Jane Giffins, Griffith University. All stock cultures were subcultured and maintained in nutrient broth at 4°C.

Evaluation of antimicrobial activity

Antimicrobial activity of the kale and spirulina extracts was determined using a modified disc diffusion assay.⁴³⁻⁴⁶ Briefly, 100µL of the each bacterial suspension in log phase was spread onto individual nutrient agar plates and the extracts were tested for antibacterial activity using 6mm sterilised filter paper discs. The discs were each infused with 10µL of the individual plant extract, allowed to dry and placed onto the inoculated plates. The plates were allowed to stand at 4°C for 2h before incubation at 37°C for 24 h. The diameters of the zones of inhibition (ZOIs) were measured to the closest whole millimetre. Each assay was performed three times in triplicate ($n=9$). Mean values ($\pm$ SEM) are reported in this study. Standard discs of ampicillin (10µg) and chloramphenicol (10µg) were obtained from Oxoid, Australia and were used as positive controls to compare antibacterial activity. Filter discs infused with 10µL of distilled water were used as a negative control.

Minimum inhibitory concentration (MIC) determination

The minimum inhibitory concentration for each extract was determined using liquid dilution MIC assays and solid phase agar disc diffusion assays.

Microplate liquid dilution MIC assay

A standard liquid dilution MIC assay¹⁵ was used to evaluate the bacterial growth inhibitory activity of the extracts and conventional antibiotics. Briefly, log phase bacterial cultures were diluted to produce a McFarlands inoculation culture. A 100µL volume of sterilized nutrient broth was dispensed into all wells of a 96 well micro-titre plate. A volume of 100µL of the plant extracts or conventional antibiotics was subsequently dispensed into separate wells of the top row of the plate. A negative control (nutrient broth), sterile control (broth without bacteria) and a sample-free culture control (to ensure the media was capable of supporting microbial growth) were also included on all plates. Each test sample or control was serially diluted down each column on the plate by doubling dilution. The assay culture inoculum (100µL, containing approximately 1×10^6 colony forming units (CFU)/mL) was then added to all wells except the sterile control wells and incubated overnight at 37°C. p-Iodonitrotetrazolium violet (INT, Sigma-Aldrich, Australia) was dissolved in sterile deionised water to a concentration of 200µg/mL. A 40µL volume of the INT solution was added into all wells and the plate was incubated for a further 6 hr at 37°C. The MIC was visually determined as the lowest dose at which colour development was inhibited.

Disc diffusion MIC assay

The minimum inhibitory concentration (MIC) of each extract was also quantified by disc diffusion assay.⁴³⁻⁴⁶ Graphs of the zone of inhibition (ZOI) versus $\ln$ concentration were plotted and MIC values were calculated by linear regression.

Artemia franciscana nauplii toxicity screening

Toxicity was tested using an adapted *Artemia franciscana* nauplii lethality assay.⁴⁷⁻⁴⁹ Briefly, *A. franciscana* nauplii were incubated in the presence of the extracts, reference toxin (1mg/mL potassium dichromate) or artificial seawater (negative control) at $25 \pm 1^\circ\text{C}$ under artificial light. All treatments were performed three times, each with internal triplicates ($n=9$). The number of dead were counted in each well at 24 h then sacrificed and the total number of nauplii in each well were counted and used to calculate the % mortality per well. LC_{50} values were calculated for each treatment using probit analysis.

Statistical analysis

Data are expressed as the mean $\pm$ SEM of three independent experiments with internal triplicates ($n=9$). One way ANOVA was used to calculate statistical significance between control and treated groups, with a P value < 0.01 considered to be statistically significant.

RESULTS

Liquid extraction yields, qualitative phytochemical screening and antioxidant capacity

Extraction of 1 g of dried plant material with various solvents yielded dried plant extracts ranging from approximately 5 mg to 355mg (Table 1). The dried extracts were resuspended in 10 mL of deionised water (containing 1% DMSO), resulting in the extract concentrations shown in Table 1. Phytochemical studies (Table 1) show that methanol and water extracted the widest range and largest amount of phytochemicals in this study. The methanolic and aqueous extracts of both kale and spirulina contained high levels of total phenolics (water soluble and insoluble phenolics) and flavonoids, as well as lower levels of tannins. The ethyl acetate extracts contained similar classes of phytochemicals, although at substantially reduced relative abundances. All extracts were completely devoid of detectable levels of alkaloids, anthraquinones,

cardiac glycosides, phytosterols and triterpenoids.

Antioxidant capacity (expressed as ascorbic acid equivalence) for the kale and spirulina extracts are presented in Table 1. The antioxidant capacity ranged from levels below the detection sensitivity of the assay (ethyl acetate extracts of both kale and spirulina) to a high of approximately 10mg ascorbic acid equivalence per gram of dried plant material extracted (methanolic kale extract). In general, the kale extracts had substantially higher antioxidant capacities than the spirulina extracts. There was no clear correlation between the solvent used for extraction and the antioxidant capacity. For kale, the methanolic extract had a substantially higher antioxidant capacity than the aqueous extract, whereas this trend was reversed for spirulina.

Antimicrobial activity

Aliquots (10 μ L) of each extract were tested in the disc diffusion assay against a panel of bacterial pathogens (Figure 1). Both the kale and spirulina methanolic and aqueous extracts displayed noteworthy growth inhibitory activity against *P. mirabilis* (both the reference and clinical isolate strains). In contrast (with the exception of the methanolic and aqueous spirulina extracts, which displayed low levels of inhibitory activity against *E. coli*), the extracts were devoid of growth inhibitory activity against the other bacterial species tested. The spirulina extracts were generally better bacterial growth inhibitors than the equivalent kale extracts. This is particularly evident for the aqueous spirulina and kale extracts against *P. mirabilis* (ZOIs of 9.2 and 7.3mm respectively against the reference strain).

The relative level of antimicrobial activity was further evaluated by determining the MIC values (Table 2) against the bacterial pathogens. The kale and spirulina aqueous extracts were particularly effective at inhibiting microbial growth, with low MIC values recorded against *P. mirabilis*, indicating the potent antimicrobial activity of these extracts. The aqueous spirulina extract was particularly strong (LD MIC values of 220 and 320 μ g/mL against the reference and clinical strains respectively), compared to the aqueous kale extract (LD MIC values of 754 μ g/mL against both the reference and clinical *P. mirabilis* strains). The methanolic extracts also had noteworthy inhibitory activity, although the methanolic kale extract (LD MIC values of 965 and

Table 1: The mass of dried extracted material, the concentration after resuspension in deionised water, qualitative phytochemical screenings and antioxidant contents of kale and spirulina extracts.

		M	W	E	M	W	E
	Mass of extract (mg)	245	230	80	155	355	50
	Concentration of extract (mg/mL)	24.5	23	8	15.5	35.5	5
Phenolics	Total phenolics	+++	+++	+	+++	+++	+
	Water soluble phenolics	+++	+++	+	+++	+++	+
	Water insoluble phenolics	+++	+++	+	+++	+++	-
	Cardiac glycosides	-	-	-	-	-	-
	Saponins	+	+	-	-	+	-
Alkaloids	Triterpenes	-	-	-	-	-	-
	Phytosterols	-	-	-	-	-	-
	Meyer test	-	-	-	-	-	-
	Wagner test	-	-	-	-	-	-
	Flavonoids	+++	+++	++	+++	++	+
Anthraquinones	Tannins	+	++	-	+	+	-
	Free	-	-	-	-	-	-
	Combined	-	-	-	-	-	-
	Antioxidant capacity	10.49	8.78	-	1.09	6.01	-

+++ indicates a large response; ++ indicates a moderate response; + indicates a minor response; - indicates no response in the assay. AA = ascorbic acid. Antioxidant capacity determined by DPPH reduction (expressed as mg AA equivalence per g plant material extracted).

Figure 1: Antibacterial activity of kale and spirulina extracts and ampicillin and chloramphenicol controls (10 μ g) measured as zones of inhibition (mm) against bacterial pathogens. Results are expressed as mean $\pm$ SEM of at least triplicate determinations. Ref = reference strains; CI = clinical isolate strains; K = kale; S = spirulina; M = methanolic extract; W = aqueous extract; E = ethyl acetate extract; Amp = ampicillin; Chl = chloramphenicol; NC = negative control. * = results that are significantly different to the negative control. 6mm line indicates the diameter of the disc.

Table 2: Minimum inhibitory concentrations ($\mu\text{g/mL}$) of kale and spirulina fruit extracts against susceptible microbial species.

		Kale extracts			Spirulina extracts			Controls		
		KM	KW	KE	SM	SW	SE	Amp	Chl	NC
<i>A. baylyi</i> (R)	DD MIC	-	-	-	-	-	-	ND	ND	ND
	LD MIC	-	-	-	-	-	-	-	2.5	-
<i>A. baylyi</i> (CI)	DD MIC	-	-	-	-	-	-	ND	ND	ND
	LD MIC	-	-	-	-	-	-	-	2.5	-
<i>A. faecalis</i>	DD MIC	-	-	-	-	-	-	ND	ND	ND
	LD MIC	-	-	-	-	-	-	2.5	2.5	-
<i>B. cereus</i>	DD MIC	-	-	-	-	-	-	ND	ND	ND
	LD MIC	-	-	-	-	-	-	1.25	2.5	-
<i>E. aerogenes</i>	DD MIC	-	-	-	-	-	-	ND	ND	ND
	LD MIC	-	-	-	-	-	-	1.25	1.25	-
<i>E. coli</i>	DD MIC	-	-	-	7655	>10,000	-	ND	ND	ND
	LD MIC	-	-	-	4750	>10,000	-	1.25	1.25	-
<i>E. faecalis</i>	DD MIC	-	-	-	-	-	-	ND	ND	ND
	LD MIC	-	-	-	-	-	-	-	2.5	-
<i>K. pneumoniae</i> (R)	DD MIC	-	-	-	-	-	-	ND	ND	ND
	LD MIC	-	-	-	-	-	-	-	1.3	-
<i>K. pneumoniae</i> (CI)	DD MIC	-	-	-	-	-	-	ND	ND	ND
	LD MIC	-	-	-	-	-	-	-	1.25	-
<i>P. mirabilis</i> (R)	DD MIC	965	1283	>10,000	3258	528	>10,000	ND	ND	ND
	LD MIC	528	754	>10,000	1675	220	>10,000	1.3	0.6	-
<i>P. mirabilis</i> (CI)	DD MIC	946	1283	>10,000	2856	625	>10,000	ND	ND	ND
	LD MIC	528	754	>10,000	1250	320	>10,000	1.3	0.6	-
<i>P. vulgaris</i>	DD MIC	-	-	-	6970	>10,000	-	ND	ND	ND
	LD MIC	-	-	-	4450	>10,000	-	2.5	1.3	-
<i>P. aeruginosa</i> (R)	DD MIC	-	-	-	-	-	-	ND	ND	ND
	LD MIC	-	-	-	-	-	-	-	2.5	-
<i>P. aeruginosa</i> (CI)	DD MIC	-	-	-	-	-	-	ND	ND	ND
	LD MIC	-	-	-	-	-	-	-	2.5	-
Toxicity	<i>Artemia nauplii</i>	1063	1458	-	-	1285	-	85*	-	-

Numbers indicate the mean MIC values of triplicate determinations expressed in $\mu\text{g/mL}$. KM = kale methanolic extract; KW = kale aqueous extract; KE = kale ethyl acetate extract; SM = spirulina methanolic extract; SW = spirulina aqueous extract; SE = spirulina ethyl acetate extract; DD = disc diffusion; LD = liquid dilution; ND = MIC values were not determined as only a single dose was screened; - indicates no inhibition (or toxicity) at any concentration tested; * = potassium dichromate was used as the positive control. Bold text indicates noteworthy MIC values.

946 $\mu\text{g/mL}$ against the reference and clinical strains respectively) was a substantially better inhibitor of *P. mirabilis* growth than the methanolic spirulina extract (LD MIC values of 3258 and 2856 $\mu\text{g/mL}$ against the reference and clinical strains respectively). All other bacteria were either completely resistant to the kale and spirulina extracts, or displayed only low inhibitory activity (as judged by MIC values).

Quantification of toxicity

The kale and spirulina extracts were diluted to 4000 $\mu\text{g/mL}$ (to give a bioassay concentration of 2000 $\mu\text{g/mL}$) in artificial seawater for toxicity testing in the *Artemia* nauplii lethality bioassay. For comparison, the reference toxin potassium dichromate was also tested in the bioassay. Potassium dichromate was rapid in its induction of mortality, with mortality evident within 4 hrs of exposure (unpublished results). The kale and spirulina extracts were slower at inducing mortality, with ≥ 12 hrs needed for mortality induction. Despite the slower onset

of mortality, the methanolic and aqueous kale extracts, as well as the aqueous spirulina extract, induced mortality significantly above that of the artificial seawater control (Figure 2). Table 2 shows the extract and control toxin concentrations required to achieve 50 % mortality (LC_{50}) at 24h. As toxicity of crude plant extracts has previously been defined as 24 LC_{50} values < 1000 $\mu\text{g/mL}$,^{47,48} the measured LC_{50} values indicate that all of the extracts were nontoxic.

DISCUSSION

The discovery of penicillin by Alexander Fleming approximately 100 years ago revolutionised medical science and provided an effective treatment against a wide variety of bacterial pathogens, thereby saving countless lives globally (as reviewed by [16]). Unfortunately, bacteria rapidly developed resistance to penicillin and by evolving to produce β -lactamase enzymes that degrade the β -lactam structure,

Figure 2: The lethality of kale and spirulina extracts (2000 µg/ml) and potassium dichromate control (1000 µg/mL) towards *Artemia franciscana* nauplii after 24 hrs exposure. Results are expressed as mean ± SEM of at least triplicate determinations. * indicates results that are significantly different to the untreated control ($p < 0.01$).

rendering those antibiotics ineffective or of low efficacy against many bacterial pathogens (as reviewed by [16]). Since then, numerous other antibiotic molecules of different classes (aminoglycosides, carbapenems, cephalosporins, fluoroquinolones, glycopeptides, macrolides, monobactams, oxazolidinones, rifamycins, sulfonamides, streptogramins and tetracyclines) have been isolated from microbes and have been incorporated into our clinical antibacterial pharmacopeia. Furthermore, synthetic chemists have modified the scaffold structures of the naturally occurring antibiotics to increase the number, efficacy and bioavailability of antibiotics available to treat bacterial infections. However, bacteria have rapidly evolved resistance mechanisms that specifically target antibiotics, rendering them resistant to their effects. There are now limited therapeutic options against many of these resistant bacterial strains and new effective antibiotic therapies are urgently needed. Indeed, the World Health Organisation (WHO) considers the development of alternative antibiotic chemotherapies to be one of the most urgent challenges for medical science (as reviewed by [16]).

A re-examination of traditional plant-based foods and medicines is a promising approach to develop new antibiotic chemotherapies. Plant-based medicines were commonly used in many cultures to treat bacterial infections before the discovery of penicillin and are still used in several traditional healing systems such as Ayurveda, or Traditional Chinese Medicine (TCM). The use of these traditional medicines is often well documented, making the selection of species for study relatively easy. Furthermore, plant preparations often contain multiple anti-pathogenic compounds, providing greater efficacy and decreasing the possibility of inducing further bacterial resistance.

The high antioxidant capacities and presence of bioactive secondary components in some 'superfoods' makes them targets for the discovery of new antibacterial chemotherapies. Both kale and spirulina have high antioxidant contents and are rich in Vitamins A, C, B1, B2, B6, E, folate and pantothenic acid, as well as iron, calcium, potassium, phosphates and manganese. Despite this, neither kale nor spirulina have been rigorously evaluated for antibacterial activity. Notably, our screening studies determined that both kale and spirulina extracts had limited specificity against the bacterial pathogens screened. The kale and spirulina extracts were particularly good inhibitors of *P. mirabilis*. This is noteworthy as *P. mirabilis* has been implicated in urinary tract infections (UTIs) and the induction of rheumatoid arthritis (RA).⁵⁰ Thus, consumption of

kale or spirulina has the potential to block RA before the induction of the immune response and inflammation, thus not only blocking the late phase symptoms, but also the tissue damage associated with RA. The methanolic spirulina extract also inhibited the growth of *E. coli*, although the MIC values indicate only weak inhibition. All extracts were completely ineffective against all other bacterial species tested, indicating a narrow specificity for these extracts.

The results of this study indicate that the kale and spirulina extracts examined in this report are worthy of further study due to their *P. mirabilis* inhibitory activity. The aqueous spirulina extract was particularly promising. Furthermore, as extracts with LC_{50} values greater than 1000 µg/mL in the *Artemia* nauplii bioassay have been defined as being non-toxic,^{47,48} all extracts were deemed to be non-toxic. Further evaluation of the antimicrobial and anticancer properties of the kale and spirulina extracts is warranted. Likewise, further bioactivity driven purification studies are needed to examine the mechanisms of action of these agents.

CONCLUSION

The results of this study demonstrate that the aqueous spirulina and kale extracts are good inhibitors of *P. mirabilis* growth, yet were ineffective against the other bacterial species tested. Bioactivity driven purifications of the active components and an examination of the mechanisms of action of these agents is required.

ACKNOWLEDGEMENT

The authors are grateful to Michelle Mendell and Jane Gifkins of Griffith University for providing the clinical bacterial strains used in this study. Financial support for this work was provided by the Environmental Futures Research Institute and the School of Environment and Science, Griffith University, Australia.

CONFLICT OF INTEREST

The authors report no conflicts of interest.

ABBREVIATIONS

DMSO: Dimethyl sulfoxide; **LC_{50} :** The concentration required to achieve 50 % mortality; **MIC:** Minimum inhibitory concentration; **ZOI:** Zone of inhibition.

REFERENCES

1. Kamboj VP. Herbal medicine. *Curr Sci*. 2000;78(1):35-9.
2. Hostettmann K, Hamburger M. Search for new lead compounds of natural origin. In *Perspectives in Medical Chemistry*. Verlag Helvetica Acta, Basel. 1993.
3. Wright MH, Sirdaarta J, White A, et al. GC-MS headspace analysis of *Terminalia ferdinandiana* fruit and leaf extracts which inhibit *Bacillus anthracis* growth. *Pharmacogn J*. 2017;9(1):73-82. DOI: 10.5530/pj.2017.1.14
4. Mpala LN, Chikowe GR, Cock IE. Growth inhibitory properties of extracts prepared from selected *Leptospermum* and *Melaleuca* species against a panel of pathogenic bacteria. *Pharmacogn Commn*. 2016;6(4):215-24. DOI: 10.5530/pc.2016.4.4
5. Omer E, Elshamy AI, Nassar M, et al. *Plantago squarrosa* Murray extracts inhibit the growth of some bacterial triggers of autoimmune diseases: GC-MS analysis of an inhibitory extract. *Inflammopharmacol*. 2018;27(2):373-85. DOI: 10.1007/s10787-018-0547-0
6. Newman DJ, Cragg GM, Snader KM. The influence of natural products on drug discovery. *Nat Prod Rep*. 2000;17(3):215-34.
7. Gaillot C, Sirdaarta J, Cock IE. Examination of the antimicrobial and anticancer properties of mangosteen. *Acta Hort*. 2016;1106:231-8.
8. Wright MH, Greene AC, Cock IE. Investigating the pharmacognostic potential of Indian *Terminalia* spp. in the treatment and prevention of yersiniosis. *Pharmacogn Commn*. 2017;7(3):108-13. DOI: 10.5530/pc.2017.3.16
9. Gilani AH, Atta-ur-Rahman. Trends in ethnopharmacology. *J Ethnopharmacol*. 2005;100(1-2):43-9.
10. Hübsch Z, Zyl RLV, Cock IE, et al. Interactive antimicrobial and toxicity profiles of

- conventional antimicrobials with Southern African medicinal plants. *S Afr J Bot.* 2014;93:185-97. DOI: 10.1016/j.sajb.2014.04.005
11. Cock IE, Vuuren SFV. Anti-Proteus activity of some South African medicinal plants: Their potential for the treatment and prevention of rheumatoid arthritis. *Inflammopharmacol.* 2014;22(1):23-36. DOI: 10.1007/s10787-013-0179-3.
 12. Omer E, Elshamy A, ElGendy AN, *et al.* *Cakile maritima* Scop. Extracts inhibit the growth of some bacterial triggers of autoimmune diseases: GC-MS analysis of an inhibitory extract. *Pharmacogn J.* 2016;8(4):361-74. DOI: 10.5530/pj.2016.4.9
 13. Biggs I, Sirdaarta J, White A, *et al.* GC-MS analysis of *Commiphora molmol* oleo-resin extracts which inhibit the growth of bacterial triggers of selected autoimmune diseases. *Pharmacogn J.* 2016;8(3):191-202. DOI: 10.5530/pj.2016.3.4
 14. Biggs I, Sirdaarta J, White A, *et al.* GC-MS analysis of frankincense extracts which inhibit the growth of bacterial triggers of selected autoimmune diseases. *Pharmacogn Commun.* 2016;6(1):10-22. DOI: 10.5530/pc.2016.1.3
 15. Fernandez A, Cock IE. *Tabebuia impetiginosa* (Mart. Ex DC. Mattos) bark extracts inhibit the growth of gastrointestinal bacterial pathogens and potentiate the activity of some conventional antibiotics. *Pharmacogn Commun.* 2020;10(2):75-82. DOI: 10.5530/pc.2020.2.15
 16. Cheesman MJ, Ilanko A, Blonk B, *et al.* Developing new antimicrobial therapies: Are synergistic combinations of plant extracts/compounds with conventional antibiotics the solution?. *Pharmacogn Rev.* 2017;11(22):57-72. DOI: 10.4103/phrev.phrev_21_17
 17. WHO. Antimicrobial Resistance. World Health Organization. 2016. Available from: <http://www.who.int/mediacentre/factsheets/fs194/en/>. [Cited on 2019 May 10].
 18. Sirdaarta J, Matthews B, Cock IE. *Kakadu plum* fruit extracts inhibit the growth of the bacterial triggers of rheumatoid arthritis: Identification of stilbene and tannin components. *J Funct Food.* 2015;17:610-20. DOI: 10.1016/j.jff.2015.06.019
 19. Ilanko A, Cock IE. The interactive antimicrobial activity of conventional antibiotics and *Petalostigma* spp. extracts against bacterial triggers of some autoimmune inflammatory diseases. *Pharmacogn J.* 2019;11(2):292-309. DOI: 10.5530/pj.2019.11.45
 20. Winnett V, Sirdaarta J, White A, *et al.* Inhibition of *Klebsiella pneumoniae* growth by selected Australian plants: Natural approaches for the prevention and management of ankylosing spondylitis. *Inflammopharmacol.* 2017;25(2):223-35. DOI: 10.1007/s10787-017-0328-1
 21. Cheesman M, White A, Matthews B, *et al.* *Terminalia ferdinandiana* fruit and leaf extracts inhibit methicillin-resistant *Staphylococcus aureus* growth. *Planta Medica.* 2019;85(16):1253-62. DOI: 10.1055/a-1013-0434
 22. Cock IE, Vuuren V. The traditional use of southern African medicinal plants for the treatment of bacterial respiratory diseases: A review of the ethnobotany and scientific evaluations. *J Ethnopharmacol.* 2020;27:113204. DOI: 10.1016/j.jep.2020.113204
 23. Courtney R, Sirdaarta J, Matthews B, *et al.* Tannin components and inhibitory activity of *Kakadu plum* leaf extracts against microbial triggers of autoimmune inflammatory diseases. *Pharmacogn J.* 2015;7(1):18-31. DOI: 10.5530/pj.2015.7.2
 24. Wright MH, Sirdaarta J, Matthews B, *et al.* Growth inhibitory activity of *Kakadu plum* extracts against the opportunistic pathogen *Clostridium perfringens*: New leads in the prevention and treatment of clostridial myonecrosis. *Pharmacogn J.* 2016;8(2):144-54. DOI: 10.5530/pj.2016.2.8
 25. Tiwana G, Cock IE, White A, *et al.* Use of specific combinations of the triphala plant component extracts to potentiate the inhibition of gastrointestinal bacterial growth. *J Ethnopharmacol.* 2020;112937. DOI: 10.1016/j.jep.2020.112937
 26. Mandeville A, Cock IE. *Terminalia chebula* Retz. fruit extracts inhibit bacterial triggers of some autoimmune diseases and potentiate the activity of tetracycline. *Indian J Microbiol.* 2018;58(4):496-506. DOI: 10.1007/s12088-018-0754-9
 27. Arkhipov A, Sirdaarta J, Rayan P, *et al.* An examination of the antibacterial, antifungal, anti-Giardial and anticancer properties of *Kigelia africana* fruit extracts. *Pharmacogn Commun.* 2014;4(3):62-76. DOI: 10.5530/pc.2014.3.7
 28. Ilanko P, McDonnell PA, Vuuren SFV, *et al.* Interactive antibacterial profile of *Moringa oleifera* Lam. Extracts and conventional antibiotics against bacterial triggers of some autoimmune inflammatory diseases. *S Afr J Bot.* 2019;124:420-35.
 29. Lee CJ, Wright MH, Arnold MSJ, *et al.* Inhibition of *Streptococcus pyogenes* growth by native Australian plants: New approaches towards the management of impetigo, pharyngitis and rheumatic heart disease. *Pharmacogn Commun.* 2016;6(3):164-73. DOI: 10.5530/pc.2016.3.6
 30. Wright MH, Sirdaarta J, White A, *et al.* GC-MS headspace analysis of *Terminalia ferdinandiana* fruit and leaf extracts which inhibit *Bacillus anthracis* growth. *Pharmacogn J.* 2017;9(1):73-82. DOI: 10.5530/pj.2017.1.14
 31. McManus K, Wood A, Wright MH, *et al.* *Terminalia ferdinandiana* Exell. extracts inhibit the growth of body odour-forming bacteria. *Internat J Cosmetic Sci.* 2017;39(5):500-10. DOI: 10.1111/ics.12403
 32. Hutchings A, Cock IE. An interactive antimicrobial activity of *Embelica officinalis* Gaertn. Fruit extracts and conventional antibiotics against some bacterial triggers of autoimmune inflammatory diseases. *Pharmacogn J.* 2018;10(4):654-62. DOI: 10.5530/pj.2018.4.108
 33. Hertog MG, Bueno-de-Mesquita HB, Fehily AM, Sweetnam PM, Elwood PC, Kromhout D. Fruit and vegetable consumption and cancer mortality in the caerphilly study. *Cancer Epidemiol Biomarkers Prev.* 1996;5(9):673-7.
 34. Vita JA. Polyphenols and cardiovascular disease: Effects on endothelial and platelet function. *Am J Clin Nutr.* 2005;81(1):292S-7S.
 35. Youdim KA, Spencer JPE, Schroeter H, Rice-Evans CA. Dietary flavonoids as potential neuroprotectants. *Biol Chem.* 2002;383(3-4):503-19.
 36. Tsuda T, Horio F, Uchida K, Aoki H, Osawa T. Dietary cyanidin 3-O-b-D-glucoside-rich purple corn colour prevents obesity and ameliorates hyperglycemia in mice. *J Nutr.* 2003;133:2125-30.
 37. Rice-Evans C, Miller N, Paganga G. Antioxidant properties of phenolic compound. *Trends Plant Sci.* 1997;2(4):152-9.
 38. US Department of Agriculture. Food data central. 2020. <https://fdc.nal.usda.gov/> cited 20 October 2020.
 39. Wright MH, Matthews B, Arnold MSJ, *et al.* The prevention of fish spoilage by high antioxidant Australian culinary plants: *Shewanella putrefaciens* growth inhibition. *Internat J Food Sci Technol.* 2016;51(3):801-13. DOI: 10.1111/ijfs.13026
 40. Rayan P, Matthews B, McDonnell PA, *et al.* *Terminalia ferdinandiana* extracts as inhibitors of *Giardia duodenalis* proliferation: A new treatment for giardiasis. *Parasitol Res.* 2015;114(7):2611-20. DOI: 10.1007/s00436-015-4465-4
 41. Noé W, Murhekar S, White A, *et al.* Inhibition of the growth of human dermatophytic pathogens by selected Australian and Asian plants traditionally used to treat fungal infections. *Journal de Mycologie Médicale.* 2019;29(4):331-44. DOI: 10.1016/j.mycmed.2019.05.003
 42. Shalom J, Cock IE. *Terminalia ferdinandiana* Exell. fruit and leaf extracts inhibit proliferation and induce apoptosis in selected human cancer cell lines. *Nutrit Cancer.* 2018;70(4):579-93. DOI: 10.1080/01635581.2018.1460680
 43. Wright MH, Sirdaarta J, White A, *et al.* GC-MS headspace analysis of *Terminalia ferdinandiana* fruit and leaf extracts which inhibit *Bacillus anthracis* growth. *Pharmacogn J.* 2017;9(1):73-82. DOI: 10.5530/pj.2017.1.14
 44. Cock IE, Wright MH, Matthews B, *et al.* Bioactive compounds sourced from *Terminalia* spp. in bacterial malodour prevention: An effective alternative to chemical additives. *Internat J Cosmetic Sci.* 2019;41(5):496-508. DOI: 10.1111/ics.12567
 45. Hutchings A, Cock IE. An interactive antimicrobial activity of *Embelica officinalis* Gaertn. Fruit extracts and conventional antibiotics against some bacterial triggers of autoimmune inflammatory diseases. *Pharmacogn J.* 2018;10(4):654-62. DOI: 10.5530/pj.2018.4.108
 46. Rabadeaux C, Vallette L, Sirdaarta J, *et al.* An examination of the antimicrobial and anticancer properties of *Khaya senegalensis* (Desr.) A. Juss. bark extracts. *Pharmacogn J.* 2017;9(4):504-18. DOI: 10.5530/pj.2017.4.82
 47. Cock IE, Ruebhart DR. Comparison of the brine shrimp nauplii bioassay and the ToxScreen-II test for the detection of toxicity associated with *Aloe vera* (*Aloe barbadensis* Miller) leaf extract. *Pharmacogn Res.* 2009;1(2):98-101.
 48. Ruebhart DR, Wickramasinghe W, Cock IE. Protective efficacy of the antioxidants vitamin E and Trolox against *Microcystis aeruginosa* and microcystin -LR in *Artemia franciscana* nauplii. *J Toxicol Environ Health Part A.* 2009;72(24):1567-75. DOI: 10.1080/15287390903232459
 49. Wright MH, Shalom J, Matthews B, *et al.* *Terminalia ferdinandiana* Exell. extracts inhibit *Shewanella* spp. growth and prevent fish spoilage. *Food Microbiol.* 2019;78:114-22. DOI: 10.1016/j.fm.2018.10.006
 50. Cock IE, Vuuren SFV. Anti-Proteus activity of some South African medicinal plants: Their potential for the treatment and prevention of rheumatoid arthritis. *Inflammopharmacol.* 2014;22(1):23-36. DOI: 10.1007/s10787-013-0179-3.

PICTORIAL ABSTRACT

SUMMARY

- Kale and spirulina extracts were screened for the ability to block the growth of a panel of human bacterial pathogens.
- The aqueous extracts of both kale and spirulina were good inhibitors of *P. mirabilis* growth (MIC values 220-754 µg/mL).
- Low or no inhibitory activity was evident against all other bacterial species.
- Toxicity of the kale and spirulina extracts was evaluated using the *Artemia* nauplii toxicity bioassay.
- All kale and spirulina extracts were non-toxic.

ABOUT AUTHORS

Dr. Ian Cock leads a research team in the Environmental Futures Research Institute and the School of Natural Sciences at Griffith University, Australia. His research involves bioactivity and phytochemical studies into a variety of plant species of both Australian and international origin, including *Aloe vera*, South Asian and South American tropical fruits, as well as Australia plants including *Scaevola spinescens*, *Pittosporum phylliraeoides*, *Terminalia ferdinandiana* (Kakadu plum), Australian *Acacias*, *Syzygiums*, *Petalostigmas* and *Xanthorrhoea johnsonii* (grass trees). This range of projects has resulted in nearly 200 publications in a variety of peer reviewed journals.